✦ LIBER ✦

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

✍ Scribed by Paul Ellis; Peter Barrett-Lee; Lindsay Johnson; David Cameron; Andrew Wardley; Susan O'Reilly; Mark Verrill; Ian Smith; John Yarnold; Robert Coleman; Helena Earl; Peter Canney; Chris Twelves; Christopher Poole; David Bloomfield; Penelope Hopwood; Stephen Johnston; Mitchell Dowsett; John MS Bartlett; Ian Ellis; Clare Peckitt; Emma Hall; Judith M Bliss

Book ID: 117304745
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 290 KB
Volume: 373
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(09)60740-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sequential docetaxel as adjuvant chemoth

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

✍ Glück, S. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Adjuvant capecitabine in combination wit

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial

✍ Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Riikka Huovinen; Arja Jukkola- 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 178 KB

Sequential versus concurrent anthracycli

Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials

✍ Nan Shao; Shenming Wang; Chen Yao; Xiangdong Xu; Yunjian Zhang; Yuanyuan Zhang; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 197 KB

Adjuvant chemotherapy and timing of tamo

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

✍ Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burto 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 145 KB

2 years versus 1 year of adjuvant trastu

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

✍ Goldhirsch, Aron; Gelber, Richard D; Piccart-Gebhart, Martine J; de Azambuja, Ev 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 449 KB

Sequential versus combination chemothera

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial

✍ Michel Ducreux; David Malka; Jean Mendiboure; Pierre-Luc Etienne; Patrick Texere 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 331 KB